Research, Fundamental

European Pharma: Top Picks as Growth Slows; New Launches and Core Products are Key

Wan Nurhayati, Equity Analyst
09 March 2023


With the conclusion of Q4 2022 results reporting period, we look back at the overall 2022 financial performance for European Pharma under our coverage and how they fared against consensus estimates, as well as the outlook for 2023.

Want to learn more? Download the Report.


Fundamental Equity Research
Gain a comprehensive view of global themes, industries, and companies.
Public Policy Research
Identify opportunity and risks driven by public policy.
Forensic Accounting Research
Understand implications of public company financial reporting.

Related Insights

Health Care REITs Poised for Healthy Returns

Health Care REITs Poised for Healthy Returns

The aging US population and increasing healthcare expenditures...
Read more